Boston Scientific (BSX) Tops Q1 EPS by 1c, Beats on Revenue; Offers FY26 EPS Guidance
Tweet
Share
E-mail
Get Alerts BSX Hot Sheet
Price: $47.80 +1.81%
Revenue Growth %: +3.7%
Financial Fact:
Net income (loss) per common share - assuming dilution: 0.17
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +3.7%
Financial Fact:
Net income (loss) per common share - assuming dilution: 0.17
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Boston Scientific (NYSE: BSX) reported Q1 EPS of $0.80, $0.01 better than the analyst estimate of $0.79. Revenue for the quarter came in at $5.2 billion versus the consensus estimate of $5.17 billion.
GUIDANCE:
Boston Scientific sees FY2026 EPS of $3.34-$3.41, versus the consensus of $3.45.
For earnings history and earnings-related data on Boston Scientific (BSX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
- Computacenter Plc. (CCC:LN) PT Raised to GBP60 at JPMorgan
- JPMorgan Upgrades Whitehaven Coal Ltd. (WHC:AU) (WHITF) to Overweight
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
